Precursor Cell Lymphoblastic Leukemia-Lymphoma: Clinical Trials

984 trials for Precursor Cell Lymphoblastic Leukemia-Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

474 completed, 146 terminated, 135 recruiting, 93 unknown. 984 Phase 2, 276 Phase 1, 47 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2984Completed 474, Terminated 146, Recruiting 135, Unknown 93, Active not recruiting 72, Withdrawn 38, Not yet recruiting 17, Suspended 6, Enrolling by invitation 3
Phase 1276Completed 110, Recruiting 46, Terminated 46, Unknown 28, Active not recruiting 26, Withdrawn 14, Not yet recruiting 5, Suspended 1
Phase 347Completed 16, Unknown 11, Recruiting 10, Terminated 5, Active not recruiting 3, Not yet recruiting 1, Withdrawn 1

Follow Precursor Cell Lymphoblastic Leukemia-Lymphoma: new trials by email Literature Review of Precursor Cell Lymphoblastic Leukemia-Lymphoma trials Research Report on Precursor Cell Lymphoblastic Leukemia-Lymphoma

Trials (filtered) newest first · largest first

All 984 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pyronaridine in Acute Myeloid Leukemia (AML)
Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Phase 2SuspendedArmaceutica, Inc.2002028-02-212026-10-19
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
Blinatumomab, olverembatinib - Phase II Clinical Trial, Blinatumomab
Phase 2Not yet recruitingM.D. Anderson Cancer Center602027-01-272026-10-07
Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL
Treatment with blinatumomab given subcutaneously. - Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia
Phase 2Not yet recruitingUniversity of Alberta802027-01-022026-08-12
CD34+ Transplants for Myeloid Malignancies
Busulfan, Melphalan, Fludarabine - Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
Phase 2Not yet recruitingGuenther Koehne502027-01-012026-10-13
Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome
Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia
Phase 2Not yet recruitingFred Hutchinson Cancer Center522027-01-012026-09-14
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute302026-12-312026-11-02
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Phase 1 / Phase 2Not yet recruitingBeOne Medicines302026-12-012026-10-26
CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study
MB-CART19.1 - Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Phase 1 / Phase 2Not yet recruitingHospital Universitario Dr. Jose E. Gonzalez302026-12-012026-10-22
Inotuzumab Plus Venetoclax in Older or Unfit Patients With Newly Diagnosed BCR::ABL1-Negative B-ALL
Inotuzumab Ozogamicin Plus Venetoclax Induction Therapy - Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP)
Phase 2Not yet recruitingRuijin Hospital352026-11-112026-11-17
Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Phase 2Not yet recruitingSWOG Cancer Research Network902026-10-142026-10-13
HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Capivasertib, Venetoclax, Dexamethasone - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
Phase 1 / Phase 2Not yet recruitingPrincess Maxima Center for Pediatric Oncology422026-10-012025-09-16
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma
Phase 2 / Phase 3Not yet recruitingChildren's Oncology Group17082026-08-282026-07-30
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone - Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Phase 1 / Phase 2RecruitingNovartis Pharmaceuticals502026-07-052026-11-12
A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
Autologous nano CD5-CAR T Cells - T-Cell Acute Lymphoblastic Leukemia, T-Lymphoblastic Lymphoma
Phase 1 / Phase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China182026-06-302026-07-01
CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
CD22 CAR-transduced T cells, Cyclophosphamide, Fludarabine - Acute Lymphoblastic Leukemia, B-All
Phase 2RecruitingNational Cancer Institute (NCI)202026-06-162026-10-26
SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS
SHR2554/AZA + Overlapped mBUCY, mBUCY conditioning Regimen Group - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Phase 2Not yet recruitingThe First Affiliated Hospital of Soochow University1802026-06-012026-06-10
SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS
SHR2554/AZA + Overlapped TBF, mBUCY conditioning regimen - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Phase 2Not yet recruitingThe First Affiliated Hospital of Soochow University1602026-06-012026-05-01
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
Phase 2SuspendedUniversity of Washington302026-05-082026-09-29
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Cord Blood Units, Total Body Irradiation, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Phase 2RecruitingMemorial Sloan Kettering Cancer Center712026-04-282026-05-14
Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity
Tirzepatide, Resistance Exercise, Lifestyle Counseling - Acute Lymphoblastic Leukemia, Obesity
Phase 2RecruitingSt. Jude Children's Research Hospital202026-04-232026-06-04

Showing 20 of 984. Sign in to see all of them.

Narrower conditions

Leukemia, Myeloid, Acute (381)  ·  Leukemia (284)  ·  Lymphoma, Non-Hodgkin (278)  ·  Myelodysplastic Syndromes (256)  ·  Burkitt Lymphoma (247)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (245)  ·  Lymphoma (218)  ·  Hodgkin Disease (198)  ·  Lymphoma, Large B-Cell, Diffuse (195)  ·  Lymphoma, Follicular (190)  ·  Lymphoma, Mantle-Cell (188)  ·  Lymphoma, B-Cell, Marginal Zone (161)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (161)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (157)

Broader conditions

Hemic and Lymphatic Diseases (984)  ·  Immunoproliferative Disorders (979)  ·  Neoplasms by Histologic Type (979)  ·  Immune System Diseases (977)  ·  Lymphatic Diseases (975)  ·  Hematologic Diseases (973)  ·  Leukemia, Lymphoid (968)  ·  Lymphoproliferative Disorders (964)  ·  Neoplasms (949)  ·  Leukemia (700)  ·  Pathological Conditions, Signs and Symptoms (479)  ·  Pathologic Processes (473)  ·  Disease Attributes (442)  ·  Leukemia, Myeloid (430)  ·  Chronic Disease (383)

Interventions

Cyclophosphamide (269)  ·  Methotrexate (155)  ·  Cytarabine (138)  ·  Vincristine (111)  ·  fludarabine phosphate (109)  ·  Dexamethasone (103)  ·  Peripheral Blood Stem Cell Transplantation (93)  ·  Etoposide (87)  ·  Filgrastim (86)  ·  fludarabine (85)  ·  Busulfan (84)  ·  Mycophenolic Acid (83)  ·  Tacrolimus (83)  ·  Whole-Body Irradiation (81)  ·  Rituximab (64)

Sponsors

Fred Hutchinson Cancer Center (69)  ·  M.D. Anderson Cancer Center (63)  ·  National Cancer Institute (NCI) (46)  ·  Masonic Cancer Center, University of Minnesota (27)  ·  St. Jude Children's Research Hospital (24)  ·  Memorial Sloan Kettering Cancer Center (22)  ·  City of Hope Medical Center (21)  ·  Novartis Pharmaceuticals (15)  ·  Children's Oncology Group (14)  ·  Gruppo Italiano Malattie EMatologiche dell'Adulto (13)  ·  Institute of Hematology & Blood Diseases Hospital, China (13)  ·  Case Comprehensive Cancer Center (12)  ·  National Heart, Lung, and Blood Institute (NHLBI) (12)  ·  The First Affiliated Hospital of Soochow University (12)  ·  Roswell Park Cancer Institute (9)

Countries

United States (634)  ·  China (94)  ·  Italy (84)  ·  Germany (69)  ·  France (67)  ·  Canada (63)  ·  United Kingdom (45)  ·  Spain (42)  ·  Netherlands (38)  ·  Australia (33)  ·  Belgium (32)  ·  South Korea (24)  ·  Russia (23)  ·  Austria (21)  ·  Japan (20)

Top investigators

Brenda Sandmaier (9)  ·  Elias Jabbour (9)  ·  Ajay Gopal (5)  ·  Elias Jabbour, MD (5)  ·  Ann E. Woolfrey, MD (4)  ·  Brandon Triplett, MD (4)  ·  Marie Bleakley (4)  ·  Partow Kebriaei, MD (4)  ·  Sima Jeha, MD (4)  ·  A. John Barrett, M.D. (3)  ·  Anjali S Advani (3)

Results publications

PMID 41671463, PMID 35622074, PMID 32499241, PMID 23524640, PMID 34515338, PMID 23065508, PMID 27209293, PMID 33242441, PMID 34048072, PMID 35007144, PMID 19141862, PMID 21527516, PMID 21623761, PMID 22133778, PMID 24862638, PMID 26432046, PMID 28054442, PMID 29358182, PMID 29618479, PMID 32619115, PMID 33496754, PMID 33741715, PMID 34267079, PMID 34353848, PMID 34432863, PMID 35422096, PMID 38551807, PMID 40195173, PMID 41592282, PMID 42154791, PMID 10204198, PMID 11408503, PMID 11675328, PMID 11972517, PMID 12011123, PMID 1403051, PMID 14767498, PMID 14966830, PMID 15107815, PMID 15253677, PMID 15315963, PMID 15817673, PMID 15929131, PMID 16115130, PMID 16155013, PMID 16195338, PMID 16344315, PMID 16564913, PMID 16775235, PMID 16809737

NIH funding

P30CA015704 (31), P01CA018029 (15), P30CA033572 (12), P01CA078902 (10), P30CA043703 (9), U10CA098543 (8), 2023 (7), P30CA015083 (7), U10CA032102 (7), 2018 (6), P30CA008748 (6), U10CA180886 (6), U10CA180888 (6), 2016 (5), 2025 (5)